الولايات المتحدة · منصات وبيانات · MarketBeat

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

نشره MarketBeat · الولايات المتحدة منذ 50 د

Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society…

اقرأ المقال كاملًا على MarketBeat سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.marketbeat.com)

يستحق القراءة أيضًا

The Motley Fool

An OpenAI Model Spent Ethereum Without Permission. Here's What That Means For Crypto Investors.

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Investing.com

Ukraine says Starshield back to normal, Musk says Kyiv violated terms

Benzinga

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Yahoo Finance

Booking vs. GameStop: Is Travel or Collectibles the Better Value Creator in Stocks?

Stocktwits